Press Releases

Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, neuroscience, and device technology, Kurve Therapeutics is paving the way for revolutionary clinical success in treating complex CNS disorders, including Alzheimer’s and Parkinson’s disease. The company recently announced new IP to target where medical formulations go in the brain. LYNNWOOD, Wash., March …

Kurve Therapeutics, Inc. Announces Development of New Intellectual Property to Target Drug Delivery in the Brain Read More »

Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology.

Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round.

Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population.

Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise.

Nasaldrugdeliveryblog.com opens lines of communication between drug delivery researchers, device manufacturers. The first blog to address issues related to nasal drug delivery formulation, research, delivery, and devices was launched by Kurve Technology, Inc., a leading developer of nasal drug delivery devices. The blog — http://www.nasaldrugdeliveryblog.com — invites scientists, researchers and pharmaceutical executives to exchange and …

Peer reviewed publications reporting the effectiveness of the Kurve intranasal insulin product Read More »